Spanish Minister of Health Mónica García called for a coordinated European strategy to address rising drug prices driven by geopolitical tensions [1].
The proposal highlights a growing concern over the stability of medicine costs across the continent. If the EU cannot stabilize these prices, national healthcare budgets may face unsustainable pressure, potentially limiting patient access to essential treatments.
Speaking Tuesday, June 16, 2026, García said that the current geopolitical situation is directly influencing the cost of pharmaceuticals [1]. She said that the European Union must move toward greater autonomy in how it produces and distributes medicine to protect citizens from external market shocks.
According to García, the solution lies in structural changes to the industry. "The EU must develop the entire value chain of medicines to deal with the pressure on prices," she said [1].
By developing the full value chain within Europe, the minister suggested the bloc could reduce its reliance on volatile global supply chains. This approach would involve increasing local production of active pharmaceutical ingredients, and streamlining the logistics of distribution across member states.
This call for coordination comes as several European nations struggle with the inflationary impact of global instability on healthcare costs. García's focus remains on the systemic vulnerabilities that allow geopolitical shifts to dictate the price of life-saving medication [1].
“The EU must develop the entire value chain of medicines to deal with the pressure on prices.”
This initiative reflects a broader trend toward 'strategic autonomy' within the European Union. By attempting to internalize the pharmaceutical value chain, the EU aims to transform healthcare from a vulnerability susceptible to global geopolitical leverage into a secured internal resource, though achieving this requires massive investment and regulatory alignment across all member states.
